X4 PHARMACEUTICALS, INC Share-based Payment Arrangement, Expense
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Payment Arrangement, Expense of $3.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2026-06-30 was $3.09M, a 312.57% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.41M, a 364.93% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.27M, a 2.44% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2025-09-30 was $760.00K, a 58.24% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2025 was $4.30M, a 47.61% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2024 was $8.20M, a 5.56% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2023 was $8.69M, a 67.09% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2022 was $5.20M, a 15.87% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.09M 10-Q · filed 2026-08-06 | $5.50M 10-Q · filed 2026-08-06 | $7.77M derived: sum of 3 quarters · filed 2026-08-06 | $8.53M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.41M 10-Q · filed 2026-05-06 | $4.68M derived: sum of 2 quarters · filed 2026-05-06 | $5.44M derived: sum of 3 quarters · filed 2026-05-06 | $6.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.03M derived: sum of 2 quarters · filed 2026-03-17 | $3.78M derived: sum of 3 quarters · filed 2026-08-06 | $4.30M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $760.00K 10-Q · filed 2025-11-05 | $1.51M derived: sum of 2 quarters · filed 2026-08-06 | $2.03M 10-Q · filed 2025-11-05 | $4.24M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $748.00K 10-Q · filed 2026-08-06 | $1.27M 10-Q · filed 2026-08-06 | $3.48M derived: sum of 3 quarters · filed 2026-08-06 | $5.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $519.00K 10-Q · filed 2026-05-06 | $2.74M derived: sum of 2 quarters · filed 2026-05-06 | $4.56M derived: sum of 3 quarters · filed 2026-05-06 | $6.98M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.04M derived: sum of 2 quarters · filed 2026-03-17 | $6.46M derived: sum of 3 quarters · filed 2026-03-17 | $8.20M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | $1.82M 10-Q · filed 2025-11-05 | $4.25M derived: sum of 2 quarters · filed 2025-11-05 | $5.99M 10-Q · filed 2025-11-05 | $8.53M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-06-30 | $2.43M 10-Q · filed 2025-08-08 | $4.17M 10-Q · filed 2025-08-08 | $6.71M derived: sum of 3 quarters · filed 2026-03-17 | $9.07M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-03-31 | $1.74M 10-Q · filed 2025-05-01 | $4.28M derived: sum of 2 quarters · filed 2026-03-17 | $6.64M derived: sum of 3 quarters · filed 2026-03-17 | $8.78M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2023-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.90M derived: sum of 2 quarters · filed 2026-03-17 | $7.04M derived: sum of 3 quarters · filed 2026-03-17 | $8.69M 10-K · filed 2026-03-17 | ||||
| 2023-09-30 | $2.36M 10-Q · filed 2024-11-13 | $4.50M derived: sum of 2 quarters · filed 2024-11-13 | $6.15M 10-Q · filed 2024-11-13 | $7.25M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-06-30 | $2.14M 10-Q · filed 2024-08-08 | $3.79M 10-Q · filed 2024-08-08 | $4.89M derived: sum of 3 quarters · filed 2025-03-26 | $6.00M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-03-31 | $1.65M 10-Q · filed 2024-05-07 | $2.75M derived: sum of 2 quarters · filed 2025-03-26 | $3.86M derived: sum of 3 quarters · filed 2025-03-26 | $5.38M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2022-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $2.22M derived: sum of 2 quarters · filed 2025-03-26 | $3.74M derived: sum of 3 quarters · filed 2025-03-26 | $5.20M 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | $1.11M 10-Q · filed 2023-11-09 | $2.63M derived: sum of 2 quarters · filed 2023-11-09 | $4.09M 10-Q · filed 2023-11-09 | $5.70M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | $1.52M 10-Q · filed 2023-08-10 | $2.98M 10-Q · filed 2023-08-10 | $4.59M derived: sum of 3 quarters · filed 2024-03-21 | $6.11M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | $1.46M 10-Q · filed 2023-05-04 | $3.07M derived: sum of 2 quarters · filed 2024-03-21 | $4.58M derived: sum of 3 quarters · filed 2024-03-21 | $6.38M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $3.13M derived: sum of 2 quarters · filed 2024-03-21 | $4.92M derived: sum of 3 quarters · filed 2024-03-21 | $6.18M 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | $1.52M 10-Q · filed 2022-11-03 | $3.31M derived: sum of 2 quarters · filed 2022-11-03 | $4.57M 10-Q · filed 2022-11-03 | $5.97M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | $1.80M 10-Q · filed 2022-08-04 | $3.06M 10-Q · filed 2022-08-04 | $4.45M derived: sum of 3 quarters · filed 2023-03-21 | $6.70M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | $1.26M 10-Q · filed 2022-05-12 | $2.66M derived: sum of 2 quarters · filed 2023-03-21 | $4.90M derived: sum of 3 quarters · filed 2023-03-21 | $6.07M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $3.64M derived: sum of 2 quarters · filed 2023-03-21 | $4.82M derived: sum of 3 quarters · filed 2023-03-21 | $5.43M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | $2.24M 10-Q · filed 2021-11-04 | $3.42M derived: sum of 2 quarters · filed 2021-11-04 | $4.03M 10-Q · filed 2021-11-04 | $4.69M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | $1.17M 10-Q · filed 2021-08-03 | $1.79M 10-Q · filed 2021-08-03 | $2.45M derived: sum of 3 quarters · filed 2022-03-17 | $3.14M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | $613.00K 10-Q · filed 2021-05-06 | $1.28M derived: sum of 2 quarters · filed 2022-03-17 | $1.97M derived: sum of 3 quarters · filed 2022-03-17 | $2.40M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | $664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.35M derived: sum of 2 quarters · filed 2022-03-17 | $1.79M derived: sum of 3 quarters · filed 2022-03-17 | $2.05M 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | $691.00K 10-Q · filed 2020-11-05 | $1.12M derived: sum of 2 quarters · filed 2020-11-05 | $1.39M 10-Q · filed 2020-11-05 | $1.67M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-06-30 | $433.00K 10-Q · filed 2020-08-04 | $695.00K 10-Q · filed 2020-08-04 | $983.00K derived: sum of 3 quarters · filed 2021-03-19 | $1.18M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-03-31 | $262.00K 10-Q · filed 2020-05-07 | $550.00K derived: sum of 2 quarters · filed 2021-03-19 | $748.00K derived: sum of 3 quarters · filed 2021-03-19 | $893.00K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2018-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $486.00K derived: sum of 2 quarters · filed 2021-03-19 | $631.00K derived: sum of 3 quarters · filed 2021-03-19 | $759.00K 10-K · filed 2021-03-19 | $5.62M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | $198.00K 10-Q · filed 2019-11-07 | $1.07M 10-Q · filed 2018-11-09 | $343.00K derived: sum of 2 quarters · filed 2019-11-07 | $471.00K 10-Q · filed 2019-11-07 | $2.68M 10-Q · filed 2018-11-09 | $336.00K derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | $145.00K 10-Q · filed 2019-08-07 | $1.05M 10-Q · filed 2018-08-13 | $273.00K 10-Q · filed 2019-08-07 | $1.62M 10-Q · filed 2018-08-13 | $138.00K derived: sum of 3 quarters · filed 2020-03-12 | $411.00K derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | $128.00K 10-Q · filed 2019-05-15 | $566.00K 10-Q · filed 2018-05-10 | -$7.00K derived: sum of 2 quarters · filed 2020-03-12 | $266.00K derived: sum of 3 quarters · filed 2020-03-12 | $438.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $138.00K derived: sum of 2 quarters · filed 2020-03-12 | $310.00K derived: sum of 3 quarters · filed 2020-03-12 | $492.00K 10-K · filed 2020-03-12 | $906.00K 10-K · filed 2019-03-11 | |||
| 2017-09-30 | $273.00K 10-Q · filed 2018-11-09 | $445.00K derived: sum of 2 quarters · filed 2018-11-09 | $627.00K 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $172.00K 10-Q · filed 2018-08-13 | $354.00K 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $182.00K 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $644.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |